France’s Sanofi – a major player in the rare disease category – is offering ... than current therapies for the disease, based on alpha-1 antitrypsin protein from the plasma of healthy ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at ...

Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company, recently shared his outlook for the stock ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin ... out of a Huntington's disease alliance with the ...

Mereo Biopharma Group Plc (MREO) has received a new Buy rating, initiated by LifeSci Capital analyst, Cory Jubinville, PhD.Don't Miss Our ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report)’s stock price reached a new 52-week low on Wednesday . The stock traded as low as $11.34 and last traded at $11.66, with a volume of 3223027 ...

or prominent changes suggestive of another disease AIH = autoimmune hepatitis; alpha-1 AT = alpha-1 antitrypsin; ANA = antinuclear antibodies; SMA = smooth muscle antibodies; anti-LKM1 ...

Fintel reports that on December 24, 2024, LifeSci Capital initiated coverage of Mereo BioPharma Group plc - Depositary ...

Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales. Read why I rate KRYS ...